Skip to main content
. Author manuscript; available in PMC: 2017 Aug 10.
Published in final edited form as: Prostate. 2016 Feb 9;76(7):624–636. doi: 10.1002/pros.23155

Figure 2. Chemotaxis of key innate effectors towards CRAMP-expressing TME.

Figure 2

The number of (A) Neutrophils (Gr-1+, CD11b+, Ly6b+), (B) Immature myeloid progenitors (IMPs) (Gr-1+, CD11b+, Ly6b−) and (C) Macrophages (Gr-1−, CD11b+, F4/80+) in the spleen of TRAMP-C1 and TRAMP-C1scram-sh tumor-bearing mice were compared to mice bearing TRAMP-C1CRAMP-sh cells at day-30 and day-50 post-implantation. (D) At day-50 post-implantation, the absolute number of neutrophils, IMPs, and macrophages in TME was analyzed. (mean ± SE, n=3) *P < 0.01 **P < 0.005 ***P < 0.001 (E) Subtypes of Gr-1+, CD11b+ cells in TRAMP-C1 tumors were defined by expression of Ly6C or Ly6G. Data is shown as mean ± SE (n=3). (F) Splenic Gr-1+, CD11b+ cells (1×106) from TRAMP-C1 tumor-bearing mice were plated in 5 μm cell culture insert in different groups pre-plated with TRAMP-C1scram-sh cells with or without WRW4 treatment, TRAMP-C1CRAMP-sh cells with or without CRAMP treatment, and CRAMP peptide only. Chemoattracted cells at the bottom chamber were counted using hemocytometer. Data is shown as mean ± SE from triplicate experiments (*P < 0.01).